BioTuesdays

Tag - ImMucin

Vaxil trial validates vaccine technology

By Len Zehr Results of a recent clinical trial of Vaxil Bio’s (TASE:VAXL) ImMucin cancer vaccine in patients with multiple myeloma has validated the company’s VaxHit technology by demonstrating safety and a strong...